When used in conjunction with traditional factors such as age, baseline PSA, and DRE, the addition of ExoDx Prostate Test and an OPKO4k score significantly improved the ability to predict patients at high-risk for PC and (more importantly), to exclude patients with high probability of clinically undetectable or indolent disease. This evidence concerns the gene KLK3 and pachyonychia congenita.